FIELD: medicine.
SUBSTANCE: group of inventions can be used to treat cancer. Disclosed is a method of treating or slowing down the progression of cancer in an individual, comprising administering to the individual an effective amount of a PD-1 antagonist antibody and an effective amount of an anti-TIGIT antagonist antibody, wherein the anti-TIGIT antagonist antibody inhibits and/or blocks the interaction of CD226 with TIGIT, wherein the anti-TIGIT antagonist antibody inhibits the interaction of the PVR with TIGIT; and wherein the anti-PD-1 antagonist antibody inhibits the binding of PD-1 to PD-L1. Also disclosed are kits for treating or slowing down the progression of cancer in an individual.
EFFECT: invention provides a synergistic effect on T-cell responses and induction of tumor-specific immunity.
31 cl, 37 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF TREATING CANCER USING ANTAGONISTS BINDING TO PD-1 AXIS AND TIGIT INHIBITORS | 2014 |
|
RU2702108C2 |
| ANTI-TIGIT ANTIBODIES AND METHODS OF USING | 2016 |
|
RU2732591C2 |
| ANTI-TIGIT ANTIBODIES AND METHODS OF USE | 2016 |
|
RU2817838C2 |
| METHODS OF TREATING CANCER USING ANTAGONISTS BINDING TO COMPONENTS OF THE SIGNAL PATH PD-1, AND TAXANES | 2014 |
|
RU2719487C2 |
| METHODS FOR TREATING CANCER, INCLUDING TIGIT-BINDING AGENTS | 2017 |
|
RU2765410C2 |
| ANTI-PD-L1 ANTIBODIES AND METHODS FOR THEIR DIAGNOSTIC USE | 2015 |
|
RU2715038C2 |
| COMPOSITIONS FOR TREATING CANCER USING ANTAGONISTS WHICH BIND TO THE PD-1 SIGNALING PATHWAY COMPONENT AND MEK INHIBITORS | 2015 |
|
RU2733735C2 |
| FGFR2 INHIBITORS SEPARATELY OR IN COMBINATION WITH IMMUNOSTIMULATING AGENTS IN CANCER TREATMENT | 2016 |
|
RU2745707C2 |
| HUMAN NECTIN-2 SPECIFIC ANTIBODIES | 2020 |
|
RU2820275C2 |
| COMBINATION THERAPY BASED ON T-CELL-ACTIVATING BISPECIFIC ANTIGEN-BINDING MOLECULES AGAINST CD3 AND FOLATE RECEPTOR 1 (FOLR1) AND ANTAGONISTS BINDING TO PD-1 AXIS | 2015 |
|
RU2753902C2 |
